Search

Author/Creator Holgado, E

1. 102P Results from a phase II trial of pembrolizumab (P) plus gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study. (15th December 2019)

Authors:
Merino, L de la Cruz; Cruz, J; Alonso, J L; Garcia, V Quiroga; Anton, F Moreno; Andres, R; Santiesteban, M; Vazquez, M Ramos; Cortes, M Gion; Cortés, J; Carrion, N Palazon; Lenza, I Ceballos; Soto, A; Casas, M; Benito, S; Montes, S Bezares; Holgado, E
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 88PRun-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast. (17th December 2018)

Authors:
Quiroga, V; Holgado, E; Alonso, J L; Andres, R; Moreno Anton, F; Alamo De La Gala, M D C; Henao, F; Cirauqui Cirauqui, B; Margeli, M; Cortes Castan, J; Gion Cortes, M; Soto, A; Benito, S; Escudero, M J; Chiesa, M; Caballero, R; Bezares Montes, S; Carrasco, E M; De La Cruz Merino, L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. (12th October 2017)

Authors:
Nuciforo, P; Pascual, T; Cortés, J; Llombart-Cussac, A; Fasani, R; Paré, L; Oliveira, M; Galvan, P; Martínez, N; Bermejo, B; Vidal, M; Pernas, S; López, R; Muñoz, M; Garau, I; Manso, L; Alarcón, J; Martínez, E; Rodrik-Outmezguine, V; Brase, J C
Journal:
Annals of oncology
Issue:
Volume 29:Number 1(2018)
Page Start:
170
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. (2nd February 2018)

Authors:
Vokes, E E; Ready, N; Felip, E; Horn, L; Burgio, M A; Antonia, S J; Arén Frontera, O; Gettinger, S; Holgado, E; Spigel, D; Waterhouse, D; Domine, M; Garassino, M; Chow, L Q M; Blumenschein, G; Barlesi, F; Coudert, B; Gainor, J; Arrieta, O; Brahmer, J
Journal:
Annals of oncology
Issue:
Volume 29:Number 4(2018)
Page Start:
959
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗